A phase II trial on the combination of bevacizumab and irinotecan in recurrent ovarian cancer.

被引：0
|
作者：
Ling, Huichung Tina
Muggia, Franco
Speyer, James L.
Curtin, John Patrick
Blank, Stephanie V.
Boyd, Leslie R.
Pothuri, Bhavana
Li, Xiaochun
Goldberg, Judith D.
Tiersten, Amy
机构：
[1] Permanente Med Grp Inc, Hayward, CA USA
[2] NYU, Sch Med, New York, NY USA
[3] Mt Sinai Med Ctr, New York, NY 10029 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2014年 / 32卷 / 15期
关键词：
D O I：
10.1200/jco.2014.32.15_suppl.5564
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
5564
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Phase II trial of bevacizumab and irinotecan in the treatment of malignant gliomas
    Goli, K. J.
    Desjardins, A.
    Herndon, J. E., II
    Rich, J. N.
    Reardon, D. A.
    Quinn, J. A.
    Sathornsumetee, S.
    Bota, D. A.
    Friedman, H. S.
    Vredenburgh, J. J.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [42] CTEP-sponsored phase II trial of bevacizumab (Avastin™) in combination with docetaxel (Taxotere®) in metastatic breast cancer.
    Ramaswamy, B
    Rhoades, CA
    Kendra, K
    Hauger, M
    Allen, J
    Jhaveri, S
    Chen, H
    Cagnoni, P
    Eckhardt, GS
    Elias, A
    Shapiro, CL
    [J]. BREAST CANCER RESEARCH AND TREATMENT, 2003, 82 : S50 - S50
  • [43] Phase II trial of the anti-VEGF antibody bevacizumab in combination with vinorelbine for refractory advanced breast cancer.
    Burstein, HJ
    Parker, LM
    Savoie, J
    Younger, J
    Kuter, I
    Ryan, PD
    Garber, JE
    Campos, SM
    Shulman, LN
    Harris, LN
    Gelman, R
    Winer, EP
    [J]. BREAST CANCER RESEARCH AND TREATMENT, 2002, 76 : S115 - S115
  • [44] Phase II trial of irinotecan in patients with metastatic epithelial ovarian cancer or peritoneal cancer
    Bodurka, DC
    Levenback, C
    Wolf, JK
    Gano, J
    Wharton, JT
    Kavanagh, JJ
    Gershenson, DM
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (02) : 291 - 297
  • [45] PHASE II TRIAL OF NINTEDANIB IN PATIENTS WITH BEVACIZUMAB-RESISTANT RECURRENT EPITHELIAL OVARIAN, TUBAL, AND PERITONEAL CANCER
    Secord, A. Alvarez
    McCollum, M.
    Davidson, B.
    Broadwater, G.
    Squatrito, R.
    Havrilesky, L.
    Gabel, A.
    Nixon, A.
    Duska, L.
    [J]. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2018, 28 : 457 - 457
  • [46] Phase II trial of nintedanib in patients with bevacizumab-resistant recurrent epithelial ovarian, tubal, and peritoneal cancer
    Secord, Angeles Alvarez
    McCollum, Michael
    Davidson, Brittany A.
    Broadwater, Gloria
    Squatrito, Robert
    Havrilesky, Laura J.
    Gabel, Anne C.
    Starr, Mark D.
    Brady, J. Chris
    Nixon, Andrew B.
    Duska, Linda R.
    [J]. GYNECOLOGIC ONCOLOGY, 2019, 153 (03) : 555 - 561
  • [47] Phase II trial of bevacizumab and pemetrexed for recurrent or persistent epithelial ovarian, fallopian tube, or primary peritoneal cancer
    Hagemann, Andrea R.
    Zighelboim, Israel
    Novetsky, Akiva Pesach
    Gao, Feng
    Massad, L. Stewart
    Thaker, Premal H.
    Powell, Matthew A.
    Mutch, David Gardner
    Wright, Jason D.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [48] Phase II clinical trial evaluating CRLX101 in recurrent ovarian, tubal, and peritoneal cancer.
    Krasner, Carolyn N.
    Birrer, Michael J.
    Berlin, Suzanne T.
    Horowitz, Neil S.
    Buss, Mary K.
    Eliasof, Scott
    Garmey, Edward Graeme
    Hennessey, Meliessa G.
    Konstantinopoulos, Panagiotis
    Matulonis, Ursula
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [49] Phase II trial of irinotecan in patients with progressive or rapidly recurrent colorectal cancer
    Rothenberg, ML
    Eckardt, JR
    Kuhn, JG
    Burris, HA
    Nelson, J
    Hilsenbeck, SG
    Rodriguez, GI
    Thurman, AM
    Smith, LS
    Eckhardt, SG
    Weiss, GR
    Elfring, GL
    Rinaldi, DA
    Schaaf, LJ
    VonHoff, DD
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1996, 14 (04) : 1128 - 1135
  • [50] A phase II trial of capecitabine (Xeloda®) in recurrent ovarian cancer
    Vasey, PA
    McMahon, L
    Paul, J
    Reed, N
    Kaye, SB
    [J]. BRITISH JOURNAL OF CANCER, 2003, 89 (10) : 1843 - 1848
12345